Saltar al contenido
PivotalWire
Domingo 11 oct 2026SEC · NASDAQ biomédico

Portada›Lunes 22 de diciembre de 2025

Biomédicas del NASDAQ ante la SEC, lunes 22 de diciembre de 2025

Los 32 documentos que 29 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. ENVBEnveric Biosciences, Inc.S-3Capacidad de emisión registradaEDGAR
    En el documentoContrasplit de accionestexto original ▸…any revisions to any of the forward-looking statements contained herein to reflect future events or developments. iv SELECTED FINANCIAL DATA REFLECTING THE REVERSE STOCK SPLIT On October 23, 2025, we effected a 1-for-12 reverse stock split (the “Reverse Stock Split”), which began trading on a split-adjusted basis on October 28, 2025, pursuant to which every 12 shares of our issued and outstanding shares of Common Stock were reclassified…
  2. ESLAEstrella Immunopharma, Inc.S-1Capacidad de emisión registradaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…other provisions of securities laws could negatively affect our stock price and adversely affect our potential results of operations, cash flow and financial condition. Our financial statements expressing substantial doubt about our ability to continue as a going concern due to our history of recurring losses and our expectation that negative cash flows from operations will continue until we can generate sufficient revenue. Our ability to continue as a going concern requires…
    En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸…which requires a minimum bid price of $1.00 per share, and the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2). In November 2024 and again in April 2025, we received notices from Nasdaq that we were not in compliance with the minimum bid price requirement, and in August 2025 we received a notice that we were not in compliance with the minimum market value of listed securities requirement. In September 2025, Nasdaq notified us that we had regained…
    En el documentoDebilidad material en el control internotexto original ▸…experience to address U.S. GAAP accounting issues and to prepare and review financial statements and related disclosures. As of September 30, 2025, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective, and this material weakness had not been remediated. If Estrella fails to establish and maintain proper internal financial reporting controls, its ability to produce accurate financial statements or comply with applicable regulations…
  3. GOVXGeoVax Labs, Inc.424B4Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…and may not remain in business. We have received a going concern opinion from our auditors. We have received a "going concern" opinion from our independent registered public accounting firm, reflecting substantial doubt about our ability to continue as a going concern. Our consolidated financial statements contemplate that we will continue as a going concern and do not contain any adjustments that might result if we were unable to continue as a going concern. Our ability…
    En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸…share price, and certain corporate governance requirements. There can be no assurances that we will be able to continue to comply with the applicable listing standards. On July 31, 2025, the “Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…primarily from sales of our equity securities and from government grants and clinical trial assistance. During 2024, we closed four registered direct offerings of our Common Stock and warrants, as well as established the ATM Program (see footnote 6 to the consolidated financial statements included in this prospectus). Net proceeds to us from these offerings, after deducting commissions to the placement agent and sales agent, as applicable…
  4. JBIOJade Biosciences, Inc.S-1Capacidad de emisión registradaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…results of its operations and its cash flows for the period from June 18, 2024 (inception) to December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt about the Company’s Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company…
    En el documentoContrasplit de accionestexto original ▸…Closing Financing were converted into shares of Common Stock in accordance with the Exchange Ratio (as defined herein). 1 Table of Contents Immediately prior to the consummation of the Merger, Aerovate effected a 1-for-35 reverse stock split of Aerovate common stock (as defined herein), which became legally effective on April 28, 2025 (the “Reverse Stock Split”). Following the Reverse Stock Split, and as a result of and upon the First Effective…
  5. ONCOOnconetix, Inc.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…assurance that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide self-sustaining cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements incorporated by reference in this prospectus do not include any adjustment that might be necessary if the Company is unable to continue as a going concern…
    En el documentoContrasplit de accionestexto original ▸…in this prospectus do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. 2 Recent Developments Reverse Stock Split On June 13, 2025, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-eighty-five (1:85). The Company accounted for the reverse stock split on a retrospective basis pursuant to Accounting Standards…
  6. QNTMQuantum Biopharma Ltd.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoContrasplit de accionestexto original ▸…provisions of the OBCA. Effective May 24, 2018, we changed our name to “FSD Pharma Inc.” Effective August 15, 2024, we changed our name from “FSD Pharma Inc.” to “Quantum BioPharma Ltd.” On August 15, 2024, we effected a one-for-sixty-five (1-for-65) Reverse Stock Split, pursuant to which our shareholders received one issued and outstanding post-Reverse Stock Split Class A Share or Class B Share, as applicable, in exchange for 65 outstanding pre-Reverse Stock Split Class…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…PROSPECTUS SUPPLEMENT (To Prospectus dated January 4, 2024) Filed pursuant to Rule 424(b)(5) Registration No. 333-276264 QUANTUM BIOPHARMA LTD. UP TO US$17,243,174 CLASS B SUBORDINATE VOTING SHARES We have entered into an At The Market Offering Agreement, or the Sales Agreement, dated as of December 22, 2025, with Rodman & Renshaw LLC, or Rodman or the Sales Agent, relating to the offering of our Class B Subordinate Voting Shares, or the Class…
  7. AKANAKANDA CORP.424B3Prospecto suplementario o de reventaEDGAR
  8. NRXPNRX Pharmaceuticals, Inc.424B3Prospecto suplementario o de reventaEDGAR
  9. OVIDOvid Therapeutics Inc.424B3Prospecto suplementario o de reventaEDGAR

Participaciones y control

  1. CDTCDT Equity Inc.SC 13D/ACambio en participación significativaEDGAR
  2. IMNMImmunome Inc.SC 13D/ACambio en participación significativaEDGAR
  3. KLRSKalaris Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
  4. LONALeonaBio, Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. NMADNOMAD POWER SOLUTIONS, INC.8-KFin de acuerdo materialEDGAR
  2. BIAFbioAffinity Technologies, Inc.8-KOtros hechos relevantesEDGAR
  3. BMRNBIOMARIN PHARMACEUTICAL INC8-KOtros hechos relevantesEDGAR
  4. ENGNenGene Therapeutics Inc.8-KResultadosEDGAR
    En el documentoDesignación de terapia avanzada (RMAT)texto original ▸…the limitations of viral-based gene therapies, reduce complexities related to safe handling and cold storage, and streamline both manufacturing processes and administration paradigms. Detalimogene has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA) based on its potential to address the high unmet medical need for patients with BCG-unresponsive carcinoma in situ…
  5. ENGNenGene Therapeutics Inc.10-KInforme anualEDGAR
  6. FLNAFILANA THERAPEUTICS, INC.8-K/ACambio en el consejo o la direcciónEDGAR
  7. GOVXGeoVax Labs, Inc.8-KNuevo acuerdo materialEDGAR
  8. JUNSJUPITER NEUROSCIENCES, INC.8-KCambio en el consejo o la direcciónEDGAR
  9. MBRXMoleculin Biotech, Inc.8-KNuevo acuerdo materialEDGAR
  10. MIRAMIRA PHARMACEUTICALS, INC.8-KCambio en el consejo o la direcciónEDGAR
  11. NAGENiagen Bioscience, Inc.8-KNuevo acuerdo materialEDGAR
    En el documentoAcuerdo de licencia o colaboracióntexto original ▸…Company all of QUB’s right, title, and interest in the patent rights previously jointly owned or licensed to the Company under the JOMA and the License Agreement. The Agreement terminated the JOMA and License Agreement, and QUB provided a broad release of royalty, payment, accounting, and other obligations arising under those prior agreements, including the royalty obligations accrued by the Company under such agreements through 2025. As consideration for the…
  12. NERVMinerva Neurosciences, Inc.8-KCambio en el consejo o la direcciónEDGAR
  13. RNAZTranscode Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
  14. RPRXRoyalty Pharma plc8-KCambio en el consejo o la direcciónEDGAR
  15. SLNSilence Therapeutics plc8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸…Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Executive Director On December 18, 2025, the Board of Directors (the “Board”) of Silence Therapeutics plc (the “Company”) appointed Rhonda Hellums, the Company’s Executive Vice President and Chief Financial Officer, to the Board, effectively immediately. In accordance with the Company’s articles of association, Ms. Hellums will serve for an initial term expiring at the end of the Company’s 2026 Annual General Meeting…
  16. SLNSilence Therapeutics plc8-K/ACambio en el consejo o la direcciónEDGAR
  17. TELOTelomir Pharmaceuticals, Inc.8-KCambio en el consejo o la direcciónEDGAR
  18. VTGNVistagen Therapeutics, Inc.8-KOtros hechos relevantesEDGAR

Juntas de accionistas

  1. ATOSATOSSA THERAPEUTICS, INC.DEF 14AConvocatoria de junta de accionistasEDGAR
    En el documentoContrasplit de accionestexto original ▸…REVERSE STOCK SPLIT We are asking our stockholders to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), which the Board has approved and declared advisable, to effect a reverse stock split (the “Reverse Stock Split”) of all issued and outstanding shares of our common stock, at a ratio ranging from 5:1 to 20:1, inclusive (“Proposal 1”). Background The primary purpose of the Reverse Stock…

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.